Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

ArmaGen forms strategic agreement with Shire to develop drug for Hunter syndrome

July 25, 2014

Neurotrope Bioscience licenses IP for Niemann-Pick Type C disease therapy

July 25, 2014

Resverlogix reports MACE data in patients with diabetes treated with RVX-2018

July 24, 2014

FDA grants orphan drug status to palovarotene for FOP

July 23, 2014

MYOS and Cloud Pharmaceuticals to develop drugs targeting sarcopenia and cachexia

July 22, 2014

ITCA-650 proves beneficial in patients with diabetes and severe hyperglycemia

July 21, 2014

ViaCyte files IND for VC-01 encapsulated cell replacement therapy for type 1 diabetes

July 21, 2014

Amgen reports first phase III trial results for AMG-416 in secondary hyperparathyroidism

July 21, 2014

Isis Pharmaceuticals begins phase II study of ISIS-APO(a)Rx in patients with high Lp(a)

July 18, 2014

Significant benefits seen with DA-1229 in diabetes trial

July 18, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...